KalVista Pharmaceuticals Presents New Data for Sebetralstat and its Oral Factor XIIa Inhibitor Program - read this article along with other careers information, tips and advice on BioSpace
Sebetralstat data examines efficacy by attack location and population PK comparisons - Preclinical data for oral Factor XIIa inhibitor shows durable suppression of kallikrein-kinin system - KalVista
05.07.2022 - KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of oral, small molecule protease inhibitors, has presented data for its oral on demand plasma . Seite 1
– Sebetralstat data examines efficacy by attack location and population PK comparisons –– Preclinical data for oral Factor XIIa inhibitor shows durable suppression of kallikrein-kinin system -CAMBRIDGE, Mass. & SALISBURY, England (BUSINESS WIRE) $KALV KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stag.